Using blood DNA tests to track PARP inhibitor response
Part of Cancer clinical trials.
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign informed consent
- You’re a man age 18 to 75
- Your prostate cancer has a specific gene fault (a “DNA repair” gene mutation) and was confirmed by testing
- Your cancer has spread and is resistant despite “castration” hormone treatment, and your doctor plans a PARP inhibitor
- Your scans show a measurable spot they can track
- You can provide an adequate archived tumor tissue sample (enough tumor cells, with limited dead/necrotic cells)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
This study uses a special PET scan (FTT-PET) and a blood test (ctDNA) to see if they can predict how well PARP inhibitor therapy works in men with metastatic prostate cancer that has specific genetic mutations. It aims to improve treatment decisions by identifying which patients benefit most from these drugs.
This research study examines circulating tumor cells (cancer cells in the bloodstream) to better understand which patients might benefit from PARP inhibitor drugs. You'll have blood samples collected to help doctors personalize cancer treatment decisions.
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.